

SEQUENCE LISTING

<110> JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
KOWA COMPANY, LTD.

<120> SEB VARIANT AND MEDICAMENT FOR PREVENTING AND TREATING IMMUNOPATHIES
CONTAINING THE SAME

<130> 664422

<150> JP 2003-91819

<151> 2003-03-28

<160> 9

<210> 1

<211> 239

<212> PRT

<213> Staphylococcus aureus

<400> 1

Glu	Ser	Gln	Pro	Asp	Pro	Lys	Pro	Asp	Glu	Leu	His	Lys	Ser	Ser	Lys
1				5					10					15	
Phe	Thr	Gly	Leu	Met	Glu	Asn	Met	Lys	Val	Leu	Tyr	Asp	Asp	Asn	His
			20					25					30		
Val	Ser	Ala	Ile	Asn	Val	Lys	Ser	Ile	Asp	Gln	Phe	Leu	Tyr	Phe	Asp
		35					40					45			
Leu	Ile	Tyr	Ser	Ile	Lys	Asp	Thr	Lys	Leu	Gly	Asn	Tyr	Asp	Asn	Val
	50					55					60				
Arg	Val	Glu	Phe	Lys	Asn	Lys	Asp	Leu	Ala	Asp	Lys	Tyr	Lys	Asp	Lys
	65				70					75					80
Tyr	Val	Asp	Val	Phe	Gly	Ala	Asn	Tyr	Tyr	Tyr	Gln	Cys	Tyr	Phe	Ser
				85				90						95	
Lys	Lys	Thr	Asn	Asp	Ile	Asn	Ser	His	Gln	Thr	Asp	Lys	Arg	Lys	Thr
			100					105					110		
Cys	Met	Tyr	Gly	Gly	Val	Thr	Glu	His	Asn	Ala	Asn	Gln	Leu	Asp	Lys
	115						120					125			
Tyr	Arg	Ser	Ile	Thr	Val	Arg	Val	Phe	Glu	Asp	Gly	Lys	Asn	Leu	Leu
	130					135					140				
Ser	Phe	Asp	Val	Gln	Thr	Asn	Lys	Lys	Lys	Val	Thr	Ala	Gln	Glu	Leu
	145				150					155					160
Asp	Tyr	Leu	Thr	Arg	His	Tyr	Leu	Val	Lys	Asn	Lys	Lys	Leu	Tyr	Glu
				165				170					175		
Phe	Asn	Asn	Ser	Pro	Tyr	Glu	Thr	Gly	Tyr	Ile	Lys	Phe	Ile	Glu	Asn
			180					185					190		
Glu	Asn	Ser	Phe	Trp	Tyr	Asp	Met	Met	Pro	Ala	Pro	Gly	Asp	Lys	Phe
		195					200					205			
Asp	Gln	Ser	Lys	Tyr	Leu	Met	Met	Tyr	Asn	Asp	Asn	Lys	Met	Val	Asp
	210					215					220				
Ser	Lys	Asp	Val	Lys	Ile	Glu	Val	Tyr	Leu	Thr	Thr	Lys	Lys	Lys	
225					230					235					

<210> 2

<211> 4

<212> PRT

<213> Artificial

<220>

<223> Modified sequence at residues No. 226 to No. 229 in SEB

<400> 2

Leu Phe Ala Ala

1 4

<210> 3

<211> 4

<212> PRT

<213> Artificial

<220>

<223> Modified sequence at residues No. 226 to No. 229 in SEB

<400> 3

Ala Thr Thr Gln

1 4

<210> 4

<211> 4

<212> PRT

<213> Artificial

<220>

<223> Modified sequence at residues No. 226 to No. 229 in SEB

<400> 4

Lys Arg Ile Ile

1 4

<210> 5

<211> 10

<212> PRT

<213> Artificial

<220>

<223> Epitope region of N23Y SEB variant

<400> 5

Ser Lys Asp Val Lys Ile Glu Val Tyr Leu

1 5 10

<210> 6

<211> 10

<212> PRT

<213> Artificial

<220>

<223> Epitope region of 42-C2 SEB variant including modified sequence at residues No. 226 to No. 229

<400> 6

Ser Leu Phe Ala Ala Ile Glu Val Tyr Leu
1 5 10

<210> 7

<211> 10

<212> PRT

<213> Artificial

<220>

<223> Epitope region of 42-C7 SEB variant including modified sequence at residues No. 226 to No. 229

<400> 7

Ser Ala Thr Thr Gln Ile Glu Val Tyr Leu
1 5 10

<210> 8

<211> 10

<212> PRT

<213> Artificial

<220>

<223> Epitope region of 4-C1 SEB variant including modified sequence at residues No. 226 to No. 229

<400> 8

Ser Lys Arg Ile Ile Ile Glu Val Tyr Leu
1 5 10

<210> 9

<211> 10

<212> PRT

<213> Artificial

<220>

<223> Epitope region of 48-C4 SEB variant including modified sequence at residues No. 226 to No. 229

<400> 9

Ser Pro Gln Pro Asp Ile Glu Val Tyr Leu
1 5 10